Brean Murray Carret & Co. Starts Synergy Pharmaceuticals (SGYP) at Buy; Second to Start, But Looking To Finish First

Brean Murray Carret & Co. initiates coverage on Synergy Pharmaceuticals (NASDAQ: SGYP) with a Buy. PT $13.00.

Analyst, Jonathan Aschoff, said, "A key investment catalyst is the Q212 release of Phase 2/3 plecanatide results in CIC, a significant de-risking event. Another important positive catalyst is the 2Q12 PDUFA date for competing drug linaclotide, which we expect to result in a approval that formally validates the mechanism, driving SGYP shares higher."

For an analyst ratings summary and ratings history on Synergy Pharmaceuticals click here. For more ratings news on Synergy Pharmaceuticals click here.

Shares of Synergy Pharmaceuticals closed at $3.99 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• TD Cowen Resumes EQT Corp. (EQT) at Hold
• Macquarie Starts H World Group Ltd. (HTHT) at Outperform
• B.Riley Resumes QuinStreet, Inc. (QNST) at Buy